|
186 Products |
| 186 Products |
|
1696 Diseases |  |
95004 News |  |
| «12...282283284285286287288289290291292...10661067» |
- || Sarclisa (isatuximab-irfc) / Sanofi
Enrollment open, Trial completion date, Trial primary completion date: IsAMYP: Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy (clinicaltrials.gov) - Aug 11, 2022
P2, N=46, Recruiting, Sponsor: Intergroupe Francophone du Myelome
Not yet recruiting --> Recruiting | Trial completion date: Aug 2024 --> Nov 2024 | Trial primary completion date: Mar 2022 --> Nov 2024
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Enrollment closed, Enrollment change, Adherence: ADITION: Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions (clinicaltrials.gov) - Aug 11, 2022
P=N/A, N=425, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Trial completion date: Aug 2024 --> Nov 2024 | Trial primary completion date: Mar 2022 --> Nov 2024 Recruiting --> Active, not recruiting | N=1000 --> 425
- | Olumiant (baricitinib) / Incyte, Eli Lilly, REGEN-COV (casirivimab/imdevimab) / Regeneron, Roche, Actemra IV (tocilizumab) / Roche, JW Pharma
Journal: Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. (Pubmed Central) - Aug 11, 2022
Recruiting --> Active, not recruiting | N=1000 --> 425 Estimating the real-time value of collecting additional evidence during the pandemic can inform policy makers and clinicians about the optimal moment to implement therapies and whether to perform further research.
- | dexamethasone / Generic mfg.
Journal: Limited Invasive Protocol: Optimizing Diagnostic Modalities in ACTH Mediated Cushing's Syndrome. (Pubmed Central) - Aug 11, 2022
Estimating the real-time value of collecting additional evidence during the pandemic can inform policy makers and clinicians about the optimal moment to implement therapies and whether to perform further research. LIPs represent an equally accurate, less invasive, and more cost-effective alternative to the CIS for distinguishing between CD and ECS.
- | Melflufen (melphalan flufenamide) / Oncopeptides
Journal: Melflufen for the treatment of multiple myeloma. (Pubmed Central) - Aug 11, 2022
Results from the phase III OCEAN study - currently under discussion with regulatory agencies in the United States and Europe - are more complex and have been put into context herein. Lastly, melflufen provides a proof-of-concept for the utility of the peptide-drug conjugate platform in relapsed/refractory MM.
- | dexamethasone / Generic mfg.
Journal: Modulating albumin-mediated transport of peptide-drug conjugates for antigen-specific Treg induction. (Pubmed Central) - Aug 11, 2022
Our findings serve as a guide to optimize the functionality of dexamethasone-antigen conjugate amid switching vaccine epitope sequences. Moreover, our study demonstrates that moderating the residues adjacent to the conjugation sites can serve as an engineering approach for future peptide-drug conjugate development.
- | dexamethasone / Generic mfg.
Preclinical, Journal: Iristectorigenin A exerts novel protective properties against airway inflammation and mucus hypersecretion in OVA-induced asthmatic mice: Iristectorigenin A ameliorates asthma phenotype. (Pubmed Central) - Aug 11, 2022
Our study provides strong evidence that Iristectorigenin A can be potential therapeutic agent ameliorating airway inflammation and mucus hypersecretion in allergic asthma. This is a first research reported the potential of Iristectorigenin A as an alternative therapeutic agent.
- | dexamethasone / Generic mfg.
Journal: Protective effects of intranasal curcumin on silica-induced lung damage. (Pubmed Central) - Aug 11, 2022
Present study shows protective effects of intranasal curcumin on silica-induced airway inflammation and structural changes thereby lung damage. Hence, it can be considered as an alternative and complementary medication for silicosis.
- | prednisolone / Generic mfg., valacyclovir / Generic mfg.
Journal: Case Report: Acute Retinal Necrosis after a Cervical Epidural Steroid Injection. (Pubmed Central) - Aug 11, 2022
The progressive nature of acute retinal necrosis is usually debilitating to vision, even when managed properly. Because prognosis is often poor, it is important to make proper diagnoses combined with a complete review of the patient's medical history and immune status to prevent further vision loss.
- | Durezol (difluprednate ophthalmic emulsion) / Senju, Novartis
Journal: Case Report: Treatment of Severe Neuroretinitis and other Sequelae Associated with Cat Scratch Disease. (Pubmed Central) - Aug 11, 2022
Oral prednisone and topical difluprednate are recommended to quell initial inflammation during the first few weeks. The anti-inflammatory effects of doxycycline and topical ketorolac used for longer duration may be beneficial in preventing tissue damage without systemic immunosuppression and result in better visual outcomes.
- | hydrocortisone / Generic mfg.
Journal: Adrenal insufficiency due to high doses of maternal corticosteroid treatment in a premature baby. (Pubmed Central) - Aug 11, 2022
The affected boy was substituted with hydrocortisone until the age of 2 years...The patient also suffers from galactosaemia. We suggest screening for AI, by testing for hypoglycaemia and hyponatraemia, in newborns who were exposed to high doses of maternal methylprednisolone treatment during the pregnancy and to include galactosaemia in national neonatal screening programmes.
- | dexamethasone / Generic mfg.
Journal: Nrf2 signaling activation by a small molecule activator compound 16 inhibits hydrogen peroxide-induced oxidative injury and death in osteoblasts. (Pubmed Central) - Aug 11, 2022
Dexamethasone- and nicotine-caused oxidative stress and death in osteoblasts were attenuated by Cpd16 as well...Importantly, weekly Cpd16 administration largely ameliorated trabecular bone loss in ovariectomy mice. Together, Cpd16 alleviates HO-induced oxidative stress and death in osteoblasts by activating Nrf2 cascade.
- | Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
Journal: Trixeo Aerosphere - Hohe Deposition in den Atemwegen. (Pubmed Central) - Aug 11, 2022
Together, Cpd16 alleviates HO-induced oxidative stress and death in osteoblasts by activating Nrf2 cascade. No abstract available
- | dexamethasone / Generic mfg.
Retrospective data, Journal: Letter to the Editor Regarding "Surgery After Primary Dexamethasone Treatment for Patients with Chronic Subdural Hematoma-A Retrospective Study". (Pubmed Central) - Aug 10, 2022
No abstract available No abstract available
- || dexamethasone / Generic mfg., ketamine / Generic mfg., paracetamol / Generic mfg.
Review, Journal: Opioid Sparing Analgesics in Spine Surgery. (Pubmed Central) - Aug 10, 2022
A narrative review of published literature was conducted using the search function in Google scholar and PubMed was used to narrow down search criteria. The keywords "analgesics," "spine," and "pain" were used.
- | prednisolone / Generic mfg.
Journal: Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease. (Pubmed Central) - Aug 10, 2022
After improving the coagulation system prolongation, the inhibitor and autoantibodies has been eradicated. Since it is suggested that drug-induced immune response can cause AiFVD, AiFVD should be considered in patients who undergo hemodialysis and develop failure of hemostasis and drug-induced eruption.
- |||||| betamethasone/calcipotriol (AKP02) / Lipidor, Menarini
Enrollment open: AKVANO-AKP02: A Phase III Study in Subjects With Mild to Moderate Psoriasis. (clinicaltrials.gov) - Aug 10, 2022
P3, N=294, Recruiting, Sponsor: Lipidor AB
Since it is suggested that drug-induced immune response can cause AiFVD, AiFVD should be considered in patients who undergo hemodialysis and develop failure of hemostasis and drug-induced eruption. Completed --> Recruiting
- | Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Enrollment open, Trial completion date, Trial primary completion date: Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma (clinicaltrials.gov) - Aug 10, 2022
P4, N=110, Recruiting, Sponsor: Hvidovre University Hospital
Completed --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
- || Decadron (dexamethasone) / Merck (MSD)
Thanks! One at SIFI, 40 mL bupi 0.25% with epi 1:400K, decadron PF 4mg. No harm in supplementing a little local at LFCN if it doesn’t look surrounded though 👁 (Twitter) - Aug 10, 2022
- | NSC23766 / University of Oslo
Journal, IO biomarker: p120 regulates E-cadherin expression in nasal epithelial cells in chronic rhinosinusitis. (Pubmed Central) - Aug 10, 2022
p120 is involved in regulating E-cadherin protein expression in CRS. Dexamethasone may alleviate the reduction in E-cadherin and p120 protein expression caused by inflammatory mediators.
- || dexamethasone / Generic mfg., melphalan / Generic mfg., lenalidomide / Generic mfg.
Review, Journal: Evidence-based medical treatment of POEMS syndrome. (Pubmed Central) - Aug 10, 2022
For transplant-ineligible patients lenalidomide-dexamethasone remains a preferred treatment option...Supportive care including management of neuropathy, endocrinopathy, thrombotic risk and anti-infective agents is necessary. Future international collaboration is crucial to define optimal treatment strategies particularly in the relapse setting.
- | methylprednisolone acetate / Generic mfg.
Journal: Resolution of feline Mycobacterium panniculitis despite protracted treatment with methylprednisolone acetate. (Pubmed Central) - Aug 10, 2022
This report details the first confirmed Mycobacterium smegmatis panniculitis in a cat in South Africa. Despite repeated treatment with methylprednisolone acetate for six months prior to diagnosis, the cat made an uneventful recovery once switched to doxycycline and marbofloxacin.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Acute Antibody-mediated Rejection Coexisting With T Cell-mediated Rejection in Pediatric ABO-incompatible Transplantation. (Pubmed Central) - Aug 10, 2022
Acute ABO-I AMR can develop simultaneously with TCMR, even in young patients with a compromised humoral immune response following ABO-I LT. Establishing the accurate diagnosis of AMR with a pathological examination, including component 4d staining, is crucial for optimizing treatment.
- | dexmedetomidine / Generic mfg.
Retrospective data, Journal: Effects of Dexmedetomidine on Hemodynamics and Anesthesia Effect of Different Doses of General Anesthesia in Patients Undergoing Hepatobiliary Surgery. (Pubmed Central) - Aug 10, 2022
Intraoperative anesthesia time, postoperative eye opening time, and extubation time of all groups are observed, and the incidences of postoperative adverse reactions are compared. The experimental results show that during general anesthesia in the liver and gallbladder surgery, the patients with high dose of DEX can better maintain the intraoperative hemodynamic parameters, and effectively restrain the postoperative stress reaction.
- || prednisone / Generic mfg., budesonide / Generic mfg.
Clinical, Journal: A Comparative Analysis of Drug Therapy, Disease Phenotype, and Health Care Outcomes for Men and Women with Inflammatory Bowel Disease. (Pubmed Central) - Aug 10, 2022
The experimental results show that during general anesthesia in the liver and gallbladder surgery, the patients with high dose of DEX can better maintain the intraoperative hemodynamic parameters, and effectively restrain the postoperative stress reaction. These findings highlight differences in disease course and treatment approaches between men and women with IBD and support the consideration of sex and gender when researching disease outcomes.
- || dexamethasone / Generic mfg.
Clinical, Journal: Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 Pneumonia: an open-label, randomised clinical trial. (Pubmed Central) - Aug 10, 2022
These findings highlight differences in disease course and treatment approaches between men and women with IBD and support the consideration of sex and gender when researching disease outcomes. Among hospitalised COVID-19 patients needing oxygen therapy, high dose of dexamethasone reduced clinical worsening within 11 days after randomisation, compared with low dose.
- | dexamethasone injection / Generic mfg.
Journal: Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study. (Pubmed Central) - Aug 10, 2022
Among hospitalised COVID-19 patients needing oxygen therapy, high dose of dexamethasone reduced clinical worsening within 11 days after randomisation, compared with low dose. Our study showed an inverse association between the chronic use of RASi and COVID-19 pneumonia severity (either ICU admissions or in-hospital death), even when significant comorbidities are considered.
- | hydrocortisone / Generic mfg.
Journal: Hypoxic and hypoglycemic brain damage as a result of an adrenal cortex crisis-An important differential diagnosis in cases of unspecific symptoms (Pubmed Central) - Aug 10, 2022
This case report demonstrates the potential symptoms, in particular a massive hypoglycemia and an initial shock refractory to catecholamine. It also shows the severity of that disease and the importance of rapid treatment even though it is difficult to make the diagnosis.
- | fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Journal: Fractional Exhaled Nitric Oxide Guided-Therapy in Chronic Obstructive Pulmonary Disease: A Stratified, Randomized, Controlled Trial. (Pubmed Central) - Aug 10, 2022
P4
It also shows the severity of that disease and the importance of rapid treatment even though it is difficult to make the diagnosis. High baseline FENO can serve as an indicator of eosinophilic airway inflammation in COPD patients who may respond favorably to treatment with inhaled corticosteroids/long-acting β-agonists.
- | Decadron (dexamethasone) / Merck (MSD)
Trial termination, Metastases: Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma (clinicaltrials.gov) - Aug 10, 2022
P1, N=27, Terminated, Sponsor: Washington University School of Medicine
High baseline FENO can serve as an indicator of eosinophilic airway inflammation in COPD patients who may respond favorably to treatment with inhaled corticosteroids/long-acting β-agonists. Active, not recruiting --> Terminated; Equipment that was used in the study was discontinued
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Surgery: Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery (clinicaltrials.gov) - Aug 10, 2022
P2, N=55, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Terminated; Equipment that was used in the study was discontinued Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2022 --> Jul 2023
- |||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
New trial, HEOR, Combination therapy, Real-world evidence, Real-world: Long-term KRd in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 10, 2022
P=N/A, N=300, Not yet recruiting, Sponsor: Dong-A University Hospital
- | Riarify (beclometasone/formoterol/glycopyrrolate) / Chiesi
New trial: TRICOLON: Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Aug 10, 2022
P=N/A, N=300, Not yet recruiting, Sponsor: Franciscus Gasthuis
- | cyclophosphamide / Generic mfg., mycophenolate mofetil / Generic mfg.
New P4 trial: MyCITS: MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN (clinicaltrials.gov) - Aug 10, 2022
P4, N=224, Recruiting, Sponsor: Second Xiangya Hospital of Central South University
- | dexamethasone / Generic mfg.
Preclinical, Journal: p-Chloro-diphenyl diselenide modulates Nrf2/Keap1 signaling and counteracts renal oxidative stress in mice exposed to dexamethasone repeated administrations. (Pubmed Central) - Aug 10, 2022
At 5 mg/kg, (p-ClPhSe)2 reduced the renal levels of 4-OH-2-HNE and HO-1 as well as modulated the Nrf2/Keap-1 signaling in mice exposed to dexamethasone. The present findings revealed that (p-ClPhSe)2 antioxidant effects were associated with the modulation of Nrf2/Keap-1 signaling pathway in the kidney of mice exposed to dexamethasone.
- || dexamethasone / Generic mfg.
Review, Journal: Perioperative Dexamethasone for Patients With Diabetes and Its Effect on Blood Glucose After Surgery. (Pubmed Central) - Aug 10, 2022
The present findings revealed that (p-ClPhSe)2 antioxidant effects were associated with the modulation of Nrf2/Keap-1 signaling pathway in the kidney of mice exposed to dexamethasone. There is not enough evidence to quantify the hyperglycemic effect of commonly used dexamethasone doses, and rigorous studies are needed to inform practice.
- | Nailike (olverembatinib) / Ascentage Pharma, lisaftoclax (APG-2575) / Ascentage Pharma
New P1 trial: Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL (clinicaltrials.gov) - Aug 10, 2022
P1, N=22, Not yet recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital
- | Stelara (ustekinumab) / J&J, Xeljanz (tofacitinib) / Pfizer, Entyvio (vedolizumab) / Takeda
Journal: Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. (Pubmed Central) - Aug 10, 2022
Methylprednisolone 40-60 mg intravenous every 24 hours or hydrocortisone 100 mg intravenous 3 times daily is appropriate for inpatient management, with methylprednisolone 40 mg being appropriate if intolerant of higher doses...It is appropriate to discharge patients on 40 mg of prednisone after observing patients for 24 hours in hospital to ensure stability before discharge...For anti-TNF-exposed patients, it is appropriate to start vedolizumab or ustekinumab for all patients and tofacitinib for those with a low risk of adverse events. No abstract available
- || budesonide / Generic mfg.
Clinical data, Journal: Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile from a Population-Based Study. (Pubmed Central) - Aug 10, 2022
No abstract available The long-term use of budesonide in MC appears to be effective and generally well tolerated with limited adverse effects.
- | formoterol fumarate / Generic mfg., budesonide inhalation suspension / Generic mfg.
Enrollment status, Trial primary completion date: ARrest RESpiraTory Failure From PNEUMONIA (clinicaltrials.gov) - Aug 10, 2022
P3, N=600, Recruiting, Sponsor: Stanford University
The long-term use of budesonide in MC appears to be effective and generally well tolerated with limited adverse effects. Enrolling by invitation --> Recruiting | Trial primary completion date: Aug 2024 --> Jul 2025
- || betamethasone sodium phosphate (SURF-200) / Harrow Health
Enrollment closed, Trial completion date, Trial primary completion date, Adverse events: Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease (clinicaltrials.gov) - Aug 10, 2022
P2, N=120, Active, not recruiting, Sponsor: Surface Pharmaceuticals, Inc.
Enrolling by invitation --> Recruiting | Trial primary completion date: Aug 2024 --> Jul 2025 Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Oct 2022 | Trial primary completion date: Jan 2023 --> Oct 2022
- || dexamethasone / Generic mfg.
Review, Journal: Rebound pain-From definition to treatment (Pubmed Central) - Aug 10, 2022
In any case, it makes sense to provide patients with comprehensive information about this special side effect of regional anaesthesia so that those affected can correctly classify the excessive pain reaction. Targeted studies to avoid severe pain after regional anaesthesia, e.g. through the addition of adjuvants, are necessary in order to keep side effects as low as possible and thereby improve patient comfort and the acceptance of regional anaesthesia.
- | triamcinolone acetonide / Generic mfg.
Journal: A Pediatric Case of Recalcitrant Nail Psoriasis Successfully Treated with a Single dose of Intralesional Triamcinolone Acetonide. (Pubmed Central) - Aug 10, 2022
Targeted studies to avoid severe pain after regional anaesthesia, e.g. through the addition of adjuvants, are necessary in order to keep side effects as low as possible and thereby improve patient comfort and the acceptance of regional anaesthesia. No abstract available
- | hydrocortisone / Generic mfg.
Retrospective data, Journal: Tolerance of hydrocortisone prophylaxis administration in extreme preterm neonates: Experience of a single UK level III neonatal unit. (Pubmed Central) - Aug 10, 2022
No abstract available Prophylactic administration of low-dose hydrocortisone for BPD to infants born below 28 weeks' gestation was not associated with an increase in serious adverse outcomes in our population.
- || dexamethasone / Generic mfg.
Clinical, Retrospective data, Review: Corticosteroids showed more efficacy in treating hospitalized patients with COVID-19 than standard care but the effect is minimal: A systematic review and meta-analysis. (Pubmed Central) - Aug 10, 2022
Five RCTs were included with 7,235 patients, of which 2,508 patients were receiving corticosteroid treatments (dexamethasone or methylprednisolone), and 4,727 received standard care...The results suggest that corticosteroids are comparable to standard care in terms of safety in treating COVID-19. Corticosteroids showed greater efficacy than standard care; however, the effect was minimal.
- | dexamethasone / Generic mfg.
Journal: Dexamethasone-loaded zeolitic imidazolate frameworks nanocomposite hydrogel with antibacterial and anti-inflammatory effects for periodontitis treatment. (Pubmed Central) - Aug 10, 2022
When evaluated on an experimental periodontitis rat model, micro-computed tomography and histological analyses showed that the nanocomposite hydrogel effectively reduced periodontal inflammation and attenuated inflammation-induced bone loss in a rat model of periodontitis. These findings suggest that the nanocomposite hydrogel might be a promising therapeutic candidate for treating periodontal disease.
- | dexamethasone injection / Generic mfg.
Journal: Impact of COVID-19-related lockdown on retinal disorders treated with intravitreal injections. (Pubmed Central) - Aug 10, 2022
These findings suggest that the nanocomposite hydrogel might be a promising therapeutic candidate for treating periodontal disease. Marginal decline in the visual acuity and worsening of the OCT features were observed as a result of delay in the IVT injections of DME, eAMD and RVO patients.
- ||| dexamethasone / Generic mfg., carfilzomib / Generic mfg., Sarclisa (isatuximab-irfc) / Sanofi
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma https://t.co/t0JRUGRBRa (Twitter) - Aug 9, 2022
- | Zilretta (triamcinolone acetonide ER) / Pacira, Monovisc (sodium hyaluronate) / Anika Therap
New P4 trial: Trial Comparing Three Single Dose Injections for Knee Osteoarthritis (clinicaltrials.gov) - Aug 9, 2022
P4, N=165, Recruiting, Sponsor: Ohio State University
- dexamethasone / Generic mfg.
Dexamethasone-loaded 3D-mesoporous nanoparticles for in-vivo sustained anti-inflammatory effects in RA | Poster Board #3135 (Hall F2 (McCormick Place Convention Center)) - Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_3165;
Finally, when the nanomedicine was applied to an in vivo RA model, there were significant anti-inflammatory effects over 8 weeks compared with the control groups. The proposed system for nanomedicine delivery could prolong the in vivo concentrations of therapeutic agents and maximize their effect, which should encourage its application.